The impact of multi-modal therapy on survival for uterine carcinosarcomas

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 419-423

  Gonzalez Bosquet, Jesus ^a   Terstriep, Shelby A ^b   Cliby, William A ^b   Brown Jones, Monica ^b   Kaur, Judith S ^b   Podratz, Karl C ^b   Keeney, Gary L ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Carcinosarcomas; FIGO staging; Treatment outcomes

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CARCINOSARCOMA; CLEAR CELL CARCINOMA; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ENDOMETRIUM CARCINOMA; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; UTERUS CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CARCINOSARCOMA; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERINE NEOPLASMS; YOUNG ADULT;

EID: 75749084357     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.10.053     Document Type: Article

References (33)

1. Brooks S.E., Zhan M., Cote T., and Baquet C.R. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol. Oncol. 93 (2004) 204-208
2. Sherman M.E., and Devesa S.S. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 98 (2003) 176-186
3. Callister M., Ramondetta L.M., Jhingran A., Burke T.W., and Eifel P.J. Malignant mixed mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 786-796
4. Bitterman P., Chun B., and Kurman R.J. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am. J. Surg. Pathol. 14 (1990) 317-328
5. Gorai I., Yanagibashi T., Taki A., Udagawa K., Miyagi E., Nakazawa T., et al. Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. Int. J. Cancer 72 (1997) 821-827
6. de Brito P.A., Silverberg S.G., and Orenstein J.M. Carcinosarcoma (malignant mixed mullerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum. Pathol. 24 (1993) 132-142
7. Silverberg S.G. Malignant mixed mesodermal tumor of the uterus: an ultrastructural study. Am. J. Obstet. Gynecol. 110 (1971) 702-712
8. George E., Manivel J.C., Dehner L.P., and Wick M.R. Malignant mixed mullerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Hum. Pathol. 22 (1991) 215-223
9. Auerbach H.E., LiVolsi V.A., and Merino M.J. Malignant mixed mullerian tumors of the uterus. An immunohistochemical study. Int. J. Gynecol. Pathol. 7 (1988) 123-130
10. Emoto M., Iwasaki H., Kikuchi M., and Shirakawa K. Characteristics of cloned cells of mixed mullerian tumor of the human uterus. Carcinoma cells showing myogenic differentiation in vitro. Cancer 71 (1993) 3065-3075
11. Schwartz S.M., Weiss N.S., Daling J.R., Gammon M.D., Liff J.M., Watt J., et al. Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus. Cancer 77 (1996) 717-724
12. Wysowski D.K., Honig S.F., and Beitz J. Uterine sarcoma associated with tamoxifen use. N. Engl. J. Med. 346 (2002) 1832-1833
13. Wickerham D.L., Fisher B., Wolmark N., Bryant J., Costantino J., Bernstein L., et al. Association of tamoxifen and uterine sarcoma. J. Clin. Oncol. 20 (2002) 2758-2760
14. Schweizer W., Demopoulos R., Beller U., and Dubin N. Prognostic factors for malignant mixed mullerian tumors of the uterus. Int. J. Gynecol. Pathol. 9 (1990) 129-136
15. Nielsen S.N., Podratz K.C., Scheithauer B.W., and O'Brien P.C. Clinicopathologic analysis of uterine malignant mixed mullerian tumors. Gynecol. Oncol. 34 (1989) 372-378
16. Dinh T.V., Slavin R.E., Bhagavan B.S., Hannigan E.V., Tiamson E.M., and Yandell R.B. Mixed mullerian tumors of the uterus: a clinicopathologic study. Obstet. Gynecol. 74 (1989) 388-392
17. Macasaet M.A., Waxman M., Fruchter R.G., Boyce J., Hong P., Nicastri A.D., et al. Prognostic factors in malignant mesodermal (mullerian) mixed tumors of the uterus. Gynecol. Oncol. 20 (1985) 32-42
18. Spanos Jr. W.J., Peters L.J., and Oswald M.J. Patterns of recurrence in malignant mixed mullerian tumor of the uterus. Cancer 57 (1986) 155-159
19. Ali S., and Wells M. Mixed Mullerian tumors of the uterine corpus: a review. Int. J. Gynecol. Can. 3 (1993) 1-11
20. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet. 105 (2009) 103-104
21. Prat J. FIGO staging for uterine sarcomas. Int. J. Gynaecol. Obstet. 104 (2009) 177-178
22. Homesley H.D., Filiaci V., Markman M., Bitterman P., Eaton L., Kilgore L.C., et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (2007) 526-531
23. Sutton G., Brunetto V.L., Kilgore L., Soper J.T., McGehee R., Olt G., et al. Trial of Ifosfamide with or without Cisplatin in Carcinosarcoma of the Uterus: a Gynecologic Oncology Group study. Gynecol. Oncol. 79 (2000) 147-153
24. Sutton G., Kauderer J., Carson L.F., Lentz S.S., Whitney C.W., and Gallion H. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol. 96 (2005) 630-634
25. Wolfson A.H., Brady M.F., Rocereto T., Mannel R.S., Lee Y.C., Futoran R.J., et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol. Oncol. 107 (2007) 177-185
26. Arrastia C.D., Fruchter R.G., Clark M., Maiman M., Remy J.C., Macasaet M., et al. Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol. Oncol. 65 (1997) 158-163
27. Bague S., Rodriguez I.M., and Prat J. Malignant mesonephric tumors of the female genital tract: a clinicopathologic study of 9 cases. Am. J. Surg. Pathol. 28 (2004) 601-607
28. Blom R., Guerrieri C., Stal O., Malmstrom H., Sullivan S., and Simonsen E. Malignant mixed mullerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases. Gynecol. Oncol. 68 (1998) 18-24
29. Pautier P., Genestie C., Rey A., Morice P., Roche B., Lhomme C., et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 88 (2000) 1425-1431
30. Sartori E., Bazzurini L., Gadducci A., Landoni F., Lissoni A., Maggino T., et al. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol. Oncol. 67 (1997) 70-75
31. Mariani A., Webb M.J., Keeney G.L., Aletti G., and Podratz K.C. Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol. Oncol. 86 (2002) 38-44
32. Mariani A., Dowdy S.C., and Podratz K.C. New surgical staging of endometrial cancer: 20 years later. Int. J. Gynaecol. Obstet. 105 (2009) 110-111
33. Maxwell G.L., Chandramouli G.V., Dainty L., Litzi T.J., Berchuck A., Barrett J.C., et al. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin. Cancer Res. 11 (2005) 4056-4066